Approval · Notice of Compliance 34185 · 2024

TYENNE: Notice of Compliance 34185

Issued October 11, 2024

A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.

Notice number: 34185
Date: October 11, 2024
Company: Fresenius Kabi Canada LtdToronto, Ontario, Canada
Product type: Biologic
Submission: New Drug Submission (NDS)
Submission class: Other
Canadian reference product: ACTEMRA

Products in this notice

Brand	DIN	Status today
TYENNE	02552469	Marketed
TYENNE	02552450	Marketed
TYENNE	02552477	Marketed
TYENNE	02552485	Marketed
TYENNE	02552493	Marketed

Medicinal ingredients

TOCILIZUMAB 200 MG per 10ML
TOCILIZUMAB 80 MG per 4ML
TOCILIZUMAB 400 MG per 20ML
TOCILIZUMAB 162 MG per 0.9ML